QTORIN 3.9% Rapamycin Anhydrous Gel
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for QTORIN 3.9% Rapamycin Anhydrous Gel, covering 2024-08-29 to 2026-03-27. Get the full timeline:
Most recent: Clinical Trial Update: SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations [Phase 3]